Liraglutide decreases energy expenditure and does not affect the fat fraction of supraclavicular brown adipose tissue in patients with type 2 diabetes |
| |
| Institution: | 1. Division of Endocrinology, Department of Medicine, University of Colorado School of Medicine (UCSOM), Denver, Colorado 80215;2. Division of Geriatrics, Department of Medicine, University of Colorado School of Medicine (UCSOM), Denver, Colorado 80215;3. Center for Women''s Health Research, Department of Medicine, University of Colorado School of Medicine (UCSOM), Denver, Colorado 80215;4. VAMC-Geriatric Research Education and Clinical Center (GRECC), Denver, Colorado 80215;5. Division of General Internal Medicine, Department of Medicine, University of Colorado School of Medicine (UCSOM), Denver, Colorado 80215;6. Division of Cardiology, Department of Medicine, University of Colorado School of Medicine (UCSOM), Denver, Colorado 80215;7. Veterans Administration Medical Center (VAMC), Denver, Colorado 80215;1. Eli Lilly and Company, Avenida de la Industria 30, 28108 Alcobendas, Madrid, Spain;2. Diabetes Unit, Endocrinology and Nutrition Department, Hospital Clínic i Universitari, Carrer de Villarroel 170, 08036 Barcelona, Spain;3. Hospital Universitario Marqués de Valdecilla, Universidad de Cantabria, Av. de Valdecilla, s/n. 39008, Santander, Spain;4. Jazz Healthcare Italy s.r.l., Italy;5. HaaPACS GmbH, Bahnhofstr. N°19 C, 69198 Schriesheim, Germany;6. Hospital Universitario Quirón Salud, Calle Diego de Velázquez, 1, 28223 Pozuelo de Alarcón, Universidad Europea de Madrid, Madrid, Spain;1. Department of Cardiology, Bispebjerg University Hospital, University of Copenhagen, Copenhagen, Denmark;2. Department of Endocrinology, Hvidovre University Hospital, University of Copenhagen, Copenhagen, Denmark;3. NNF Center for Basic Metabolic Science and Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark;4. Department of Endocrinology, Bispebjerg University Hospital, University of Copenhagen, Copenhagen, Denmark |
| |
| Abstract: | Background and aimsSeveral studies have shown that glucagon-like peptide-1 (GLP-1) analogues can affect resting energy expenditure, and preclinical studies suggest that they may activate brown adipose tissue (BAT). The aim of the present study was to investigate the effect of treatment with liraglutide on energy metabolism and BAT fat fraction in patients with type 2 diabetes.Methods and resultsIn a 26-week double-blind, placebo-controlled trial, 50 patients with type 2 diabetes were randomized to treatment with liraglutide (1.8 mg/day) or placebo added to standard care. At baseline and after treatment for 4, 12 and 26 weeks, we assessed resting energy expenditure (REE) by indirect calorimetry. Furthermore, at baseline and after 26 weeks, we determined the fat fraction in the supraclavicular BAT depot using chemical-shift water-fat MRI at 3T. Liraglutide reduced REE after 4 weeks, which persisted after 12 weeks and tended to be present after 26 weeks (week 26 vs baseline: liraglutide ?52 ± 128 kcal/day; P = 0.071, placebo +44 ± 144 kcal/day; P = 0.153, between group P = 0.057). Treatment with liraglutide for 26 weeks did not decrease the fat fraction in supraclavicular BAT (?0.4 ± 1.7%; P = 0.447) compared to placebo (?0.4 ± 1.4%; P = 0.420; between group P = 0.911).ConclusionTreatment with liraglutide decreases REE in the first 12 weeks and tends to decrease this after 26 weeks without affecting the fat fraction in the supraclavicular BAT depot. These findings suggest reduction in energy intake rather than an increase in REE to contribute to the liraglutide-induced weight loss.Trial registry numberNCT01761318. |
| |
| Keywords: | GLP-1 analogue Liraglutide Energy expenditure Brown adipose tissue Magnetic resonance imaging |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
